Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?

Benzinga_recent_news2025-12-23

Are There Red Flags in the Trial Results? Introduction: Corcept Therapeutics' (CORT) Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593431913?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com//next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240?op=imageView2&mode=2&width=256&height=256&quality=70&format=png","is_english":true,"pubTime":"2025-12-23 00:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593431913","market":"hk","top_or_hot":-1,"title":"Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?","media":"Benzinga_recent_news","content":"<div>\n<p>Are There Red Flags in the Trial Results?\nIntroduction:\nCorcept Therapeutics' (CORT) Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory ...</p>\n\n<a href=\"https://www.benzinga.com/Opinion/25/12/49541761/corcept-therapeutics-upcoming-fda-decision-is-a-crl-likely\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-23 00:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/Opinion/25/12/49541761/corcept-therapeutics-upcoming-fda-decision-is-a-crl-likely><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Are There Red Flags in the Trial Results?\nIntroduction:\nCorcept Therapeutics' (CORT) Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory ...</p>\n\n<a href=\"https://www.benzinga.com/Opinion/25/12/49541761/corcept-therapeutics-upcoming-fda-decision-is-a-crl-likely\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0566484027.USD","symbol_name":"安本美国小盘成长股","start_time":0,"source_url":"https://www.benzinga.com/Opinion/25/12/49541761/corcept-therapeutics-upcoming-fda-decision-is-a-crl-likely","article_id":"2593431913","we_media_id":null,"thumbnails":["https://static.tigerbbs.com//next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240?op=imageView2&mode=2&width=256&height=256&quality=70&format=png"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/25/12/49541761/corcept-therapeutics-upcoming-fda-decision-is-a-crl-likely","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593431913","pubTimestamp":1766421660,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Are There Red Flags in the Trial Results?Corcept Therapeutics'  Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory milestone is financially pivotal for Corcept to reduce sole reliance on Korlym for revenue generation and shift towards a multi-asset profitability company. If Relacirilant's PDUFA outcome is unfavorable, it would significantly affect Corcept's valuation, since they will have no other pre-registration drug expected to reach approval in the next 3-5 years.Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0566484027.USD":"安本美国小盘成长股","CORT":"Corcept医疗","BK4532":"文艺复兴科技持仓","BK4121":"生命科学工具和服务","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","CRL":"查尔斯河","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4530":"医药外包概念","BK4007":"制药","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Corcept Therapeutics即将做出的FDA决定：CRL可能吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":1.5,"CORT":1.5},"content_text":"Are There Red Flags in the Trial Results?\nIntroduction:\nCorcept Therapeutics' (CORT) Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory milestone is financially pivotal for Corcept to reduce sole reliance on Korlym for revenue generation and shift towards a multi-asset profitability company.  If Relacirilant's PDUFA outcome is unfavorable, it would significantly affect Corcept's valuation, since they will have no other pre-registration drug expected to reach approval in the next 3-5 years.\nClinical & Regulatory Assessment:\nRelacorilant, developed by Corcept Therapeutics (NASDAQ:CORT), is a selective glucocorticoid receptor (GR) antagonist designed to control hypercortisolism symptoms in endogenous Cushing's syndrome.  Relacorilant's NDA is primarily supported by data from two Phase 3 trials: GRACE and GRADIENT.\nIn the GRACE trial, which enrolled patients with endogenous Cushing's syndrome of all etiologies, relacorilant met its primary endpoint where patients switched to placebo had a significantly higher risk of losing hypertension control. Whereas in the GRADIENT trial, which enrolled patients with adrenal-origin Cushing's syndrome, relacorilant did not met its primary endpoint to reduce mean systolic blood pressure. This suggests that relacorilant might be more effective in endogenous Cushing syndrome patients with non-adrenal atieology, which is the majority of them. But given that the indication for NDA is all endogenous Cushing Syndrome patients (including patients with adrenal adenoma), the failure to meet primary endpoint in GRADIENT trial might increase the risk of getting complete response letter for this application. Despite this, the safety profile of relacorilant is favorable.\nFinancial position outlook:\nWith a market capitalization of  8.9 billion, Corcept Therapeutics holds a strong liquidity position with no long-term debt. Although both R&D and SG&A have increased in recent quarters, there is nothing alarming since it is consistent with company's expanding clinical activities and commercialization preparation prior to Relacorliant PDUFA event.\nCorcept Therapeutics' share outstanding remained basically unchanged and there is no sign of imminent dilution due to urgent equity financing. This is largely attributable to increase in revenue from further commercialization of their first approved drug Korlym, which allows the company to fund pipeline development. Overall, Corcept is currently in a solid financial position.\nBenzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593431913","isCrawlerRequest":true}